| Literature DB >> 29997519 |
María A Domínguez-Sanchéz1, Rosa H Bustos-Cruz2, Gina P Velasco-Orjuela3, Andrea P Quintero3, Alejandra Tordecilla-Sanders3, Jorge E Correa-Bautista3, Héctor R Triana-Reina4, Antonio García-Hermoso5, Katherine González-Ruíz6, Carlos A Peña-Guzmán7, Enrique Hernández3, Jhonatan C Peña-Ibagon3, Luis A Téllez-T3, Mikel Izquierdo8, Robinson Ramírez-Vélez3.
Abstract
The purpose of this study was to compare the neurotrophic factor response following one session of high-intensity exercise, resistance training or both in a cohort of physically inactive overweight adults aged 18-30 years old. A randomized, parallel-group clinical trial of 51 men (23.6 ± 3.5 years; 83.5 ± 7.8 kg; 28.0 ± 1.9 kg/m2) who are physically inactive (i.e., < 150 min of moderate-intensity exercise per week or IPAQ score of <600 MET min/week for >6 months) and are either abdominally obese (waist circumference ≥90 cm) or have a body mass index, BMI ≥25 and ≤ 30 kg/m2 were randomized to the following four exercise protocols: high-intensity exercise (4 × 4 min intervals at 85-95% maximum heart rate [HRmax] interspersed with 4 min of recovery at 75-85% HRmax) (n = 14), resistance training (12-15 repetitions per set, at 50-70% of one repetition maximum with 60 s of recovery) (n = 12), combined high-intensity and resistance exercise (n = 13), or non-exercising control (n = 12). The plasma levels of neurotrophin-3 (NT-3), neurotrophin-4 (also known as neurotrophin 4/5; NT-4 or NT-4/5), and brain-derived neurotrophic factor (BDNF) were determined before (pre-exercise) and 1-min post-exercise for each protocol session. Resistance training induced significant increases in NT-3 (+39.6 ng/mL [95% CI, 2.5-76.6; p = 0.004], and NT-4/5 (+1.3 ng/mL [95% CI, 0.3-2.3; p = 0.014]), respectively. Additionally, combined training results in favorable effects on BDNF (+22.0, 95% CI, 2.6-41.5; p = 0.029) and NT-3 (+32.9 ng/mL [95% CI, 12.3-53.4; p = 0.004]), respectively. The regression analysis revealed a significant positive relationship between changes in BDNF levels and changes in NT-4/5 levels from baseline to immediate post-exercise in the combined training group (R2 = 0.345, p = 0.034) but not the other intervention groups. The findings indicate that acute resistance training and combined exercise increase neurotrophic factors in physically inactive overweight adults. Further studies are required to determine the biological importance of changes in neurotrophic responses in overweight men and chronic effects of these exercise protocols. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02915913 (Date: September 22, 2016).Entities:
Keywords: exercise; inactivity; neurotrophic factors; obesity; plasticity
Year: 2018 PMID: 29997519 PMCID: PMC6030369 DOI: 10.3389/fphys.2018.00741
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Inclusion/exclusion criteria.
| a. Inactive: no participation in supervised exercise more than once a week for the previous 6 months, according to the IPAQ score of <600 MET min/week | a. Systemic infections |
| b. Central obesity: waist circumference ≥90 cm or excess weight: body mass index ≥25 and ≤30 kg/m2 | b. Weight loss or gain of >10% of body weight in the past 6 months for any reason |
| c. Interested in improving cardiovascular health and physical fitness | c. Currently taking medication that suppresses or stimulates appetite |
| d. Written informed consent | d. Uncontrolled hypertension: systolic blood pressure 160 mmHg or diastolic blood pressure 95 mmHg on treatment |
| e. Interested in improving cardiovascular health and physical fitness | e. Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or abdominal surgery (e.g., gastrostomy) |
| f. Asthma | |
| g. Diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dL), or use of any anti-diabetic medications | |
| h. Currently taking antidepressant, steroid, or thyroid medication, unless dosage instable (no change for 6 months) | |
| i. Current exerciser (>30 min organized exercise per week) | |
| j. Indication of unsuitability of current health for exercise protocol (Physical Activity Readiness. Questionnaire, PARQ) | |
| k. Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial |
Figure 1Run-in training interventions. (A), HIIT group; (B), RT group. Combined training group were received both the HIIT and RT protocols as described above.
Figure 2The BrainFit Trial Flow Diagram. Those whose blood samples (n = 5) were technically inadequate and not analyzed. BMI, body mass index.
Baseline participant characteristics by group training.
| Age, y | 24.7 (3.4) | 24.5 (3.7) | 22.8 (3.1) | 22.2 (3.4) |
| Weight, kg | 88.6 (8.9) | 81.7 (6.7) | 83.9 (7.4) | 80.6 (6.7) |
| Height, m | 1.75 (0.05) | 1.72 (0.05) | 1.68 (0.18) | 1.69 (0.05) |
| BMI, kg/m2 | 28.7 (2.0) | 27.4 (1.7) | 27.8 (1.3) | 28.1 (1.2) |
| Waist circumference, cm | 97.9 (6.3) | 95.3 (4.9) | 94.1 (4.6) | 96.9 (5.8) |
| Body fat percentage, % | 28.7 (4.1) | 26.2 (4.3) | 27.0 (3.7) | 28.1 (3.6) |
| VO2max, ml·kg·min−1 | 41.2 (17.3) | 40.6 (16.7) | 38.9 (10.5) | 37.8 (13.6) |
| EE during exercise, Kcal | – | 462.6 (74.9) | 460.9 (86.7) | 461.7 (59.1) |
| Bicep screw curl, 1RM | 25.6 (11.6) | 23.4 (7.9) | 21.9 (10.3) | 20.9 (6.9) |
| Triceps extension, 1RM | 16.1 (5.7) | 16.1 (5.3) | 17.1 (4.9) | 17.9 (4.0) |
| Dumbbell side lateral, 1RM | 9.0 (1.9) | 10.8 (3.6) | 8.9 (1.9) | 10.2 (3.3) |
| Military press, 1RM | 25.8 (9.4) | 23.0 (8.3) | 22.8 (13.5) | 19.0 (5.1) |
| Dumbbell squat, 1RM | 47.8 (23.0) | 55.0 (34.4) | 53.3 (14.1) | 52.8 (23.5) |
| Dumbbell front lunge, 1RM | 28.4 (7. 7) | 28.0 (16.2) | 22.7 (6.6) | 26.3 (10.7) |
| Total muscle strength, (kg; total of six exercises) | 142.7 (43.7) | 156.3 (53.4) | 136.5 (34.6) | 147.2 (38.5) |
| BDNF, ng/mL* | 176.8 (37.6) | 161.1 (24.7) | 166.0 (30.5) | 189.1 (27.0) |
| NT-3, ng/mL* | 247.5 (20.5) | 285.4 (41.5) | 315.1 (28.6) | 275.3 (38.3) |
| NT-4/5, ng/mL* | 14.3 (1.7) | 18.0 (1.7) | 16.4 (1.8) | 17.4 (1.7) |
Data in mean (standard deviation) or (SEM).
Intent-to-treat analysis of BDNF, NT-3, and NT-4/5 at baseline and changes after acute effect.
| HIIT training, ( | 161.0 (23.1) | 172.1 (25) | +6.8 (0.134) | 11.05 (3.8 to 26.0) | – | – |
| RT training, ( | 166.0 (30.6) | 181.5 (31.2) | +9.3 (0.066) | 15.5 (−1.2 to 32.3) | – | – |
| Combined training, ( | 189.1 (29.7) | 211.2 (34) | +11.6 (0.029) | 22.0 (2.6 to 41.5) | – | – |
| Control group, ( | 176.7 (38.7) | 177.9 (38.4) | +0.6 (0.804) | 1.19 (−11.6 to 9.2) | – | – |
| Δ Combined vs. Δ control | – | – | – | – | 20.8 (−0.1 to 41.8) | 1.412 (0.083) |
| Δ HIIT vs. Δ control | – | – | – | – | 9.8 (−10.7 to 30.4) | |
| Δ RT vs. Δ control | – | – | – | – | 14.3 (−35.7 to 7.0) | |
| Δ Combined vs Δ HIIT | – | – | – | – | 11.0 (−9.1 to 31.2) | |
| Δ RT vs. Δ HIIT | – | – | – | – | 4.4 (−16.1 to 25.0) | |
| Δ Combined vs. Δ RT | – | – | – | – | 6.5 (−14.4 to 27.5) | |
| HIIT training, ( | 285.3 (46.3) | 322.4 (41.5) | +12.5 (0.097) | 37.4 (−7.7 to 81.7) | – | – |
| RT training, ( | 315.1 (28.6) | 354.6 (28.6) | +13.0 (0.038) | 39.6 (2.5 to 76.6) | – | – |
| Combined training, ( | 275.2 (33.7) | 308.1 (38.9) | +11.9 (0.004) | 32.9 (12.3 to 53.4) | – | – |
| Control group, ( | 247.4 (26.4) | 250.0 (25.3) | +1.0 (0.638) | 2.5 (−8.9 to 14.0) | – | – |
| Δ Combined vs Δ control | – | – | – | – | 30.4 (−12.4 to 73.2) | 1.280 (0.076) |
| Δ HIIT vs Δ control | – | – | – | – | 34.5 (−7.5 to 76.5) | |
| Δ RT vs Δ control | – | – | – | – | 37.0 (−6.5 to 80.7) | |
| Δ Combined vs Δ HIIT | – | – | – | – | −4.1 (−45.3 to 37.0) | |
| Δ RT vs Δ HIIT | – | – | – | – | 2.5 (−39.5 to 44.6) | |
| Δ Combined vs Δ RT | – | – | – | – | −6.6 (−49.5 to 36.1) | |
| HIIT training, ( | 17.9 (2.56) | 18 (2.32) | +0.5 (0.870) | 0.1 (−1.5 to 1.8) | – | – |
| RT training, ( | 16.4 (2.0) | 17.5 (2.4) | +6.7 (0.014) | 1.3 (0.3 to 2.3) | – | – |
| Combined training, ( | 17.3 (1.9) | 18.9 (2.5) | +9.2 (0.246) | 1.5 (−1.2 to 4.3) | – | – |
| Control group, ( | 14.2 (2.3) | 14.8 (2.5) | +4.2 (0.175) | −0.6 (−0.3 to 1.5) | – | – |
| Δ Combined vs Δ control | – | – | – | – | 0.9 (−1.4 to 3.3) | 0.649 (0.040) |
| Δ HIIT vs Δ control | – | – | – | – | −0.4 (−2.8 to 1.9) | |
| Δ RT vs Δ control | – | – | – | – | 0.7 (−1.7 to 3.2) | |
| Δ Combined vs Δ HIIT | – | – | – | – | 1.4 (−0.8 to 3.7) | |
| Δ RT vs Δ HIIT | – | – | – | – | 1.2 (−1.1 to 3.5) | |
| Δ Combined vs Δ RT | – | – | – | – | 0.2 (−2.1 to 2.6) | |
Data in standard error of the mean (SEM) or (95% CI). HIIT, high–intensity interval training; RT, resistant training; BDNF, brain–derived neurotrophic factor; NT-3, neurotrophin-3; NT-4/5, neurotrophin-4/5; (–), not applicable; Δ, within–group change. η.
Figure 3The regression analysis revealed a significant positive relationship between changes in BDNF levels and changes in NT-4/5 levels from baseline to immediate post-exercise in the combined training group (R2 = 0.345, p = 0.034; C). Additionally, no relationship was found between changes in BDNF levels and changes in NT-3 levels (A,B,D).